Under what circumstance/s is it appropriate to initiate treatment for hypertension with a single drug (followed by titration, additional agents)?
Gregory W. Rutecki, MD
The optimal choice of medication to bind excess phosphate in patients with advanced CKD won't always be straightforward.
When should you consider coronary artery calcium scoring to determine CV risk in your patients? Our author found some solid guidance.
A subanalysis of the COMPASS trial found that combination treatment with rivaroxaban and aspirin reduced incidence of major adverse limb events by 43%.
A look back at a decade of advances in management of peripheral vascular disease prompted this short summary of big changes.
Severe hypoglycemia was associated with death within ~1 week among patients with T2DM, according to a subanalysis of the LEADER trial.
When CKD 4-5 progresses to ESRD, how should hypertension management be changed? Or, should it?
Hypertension in persons with HIV is a significant CV risk factor and should be a target of focused prevention in primary care.
After stroke and bleeding risk are calculated and anticoagulation commences, hypertension control is essential to prevent CV events.
The author wants your opinion on the habitual titration of β-blockers in patients with comorbid HF who are not at BP goal.